PNC FINANCIAL SERVICES GROUP, INC. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$34,637
-40.4%
1,679
-14.8%
0.00%
Q2 2023$58,164
+73.4%
1,971
+35.4%
0.00%
Q1 2023$33,546
-27.7%
1,456
-12.8%
0.00%
Q4 2022$46,415
+71.9%
1,669
+85.2%
0.00%
Q3 2022$27,000
+12.5%
901
+10.1%
0.00%
Q2 2022$24,000
-11.1%
818
-2.4%
0.00%
Q1 2022$27,000
-58.5%
838
-42.3%
0.00%
Q4 2021$65,000
+6.6%
1,452
+19.9%
0.00%
Q3 2021$61,000
-16.4%
1,211
+30.4%
0.00%
Q2 2021$73,000
+40.4%
929
+1.3%
0.00%
Q1 2021$52,000
-33.3%
917
-1.1%
0.00%
Q4 2020$78,000
+136.4%
927
+0.3%
0.00%
Q3 2020$33,000
+50.0%
9240.0%0.00%
Q2 2020$22,000
+37.5%
924
+0.8%
0.00%
Q1 2020$16,000
+77.8%
917
+83.4%
0.00%
Q4 2019$9,000
+12.5%
5000.0%0.00%
Q3 2019$8,000
-20.0%
5000.0%0.00%
Q2 2019$10,000
-16.7%
5000.0%0.00%
Q1 2019$12,000
+20.0%
5000.0%0.00%
Q4 2018$10,000
-16.7%
500
-6.7%
0.00%
Q3 2018$12,000
+50.0%
536
+7.2%
0.00%
Q2 2018$8,0005000.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders